<PAGE>
--------------------------------
OMB APPROVAL
--------------------------------
OMB Number: 3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response...... 14.90
--------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )*
-----
UroGen Corp.
-------------------------------------------------------------
(Name of Issuer)
Common Stock
---------------------------------------------------
(Title of Class of Securities)
(None)
-----------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 5 Pages
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 13G PAGE 2 OF 5 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Sydney Kimmel Cancer Center
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
N/A
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
California
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 339,000
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
-0-
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 339,000
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
-0-
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
339,000
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
N/A
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11
5.6%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
CO
- ------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
Page 2 of 5 pages
<PAGE>
CUSIP No. _______________ Page 3 of 5 Pages
Item 1(a) Name of Issuer:
UroGen Corp.
Item 1(b) Address of Issuer's Principal Executive Offices:
3099 Science Park Road, Suite A
San Diego, CA 92121
Item 2(a) Name of Person(s) Filing:
Sydney Kimmel Cancer Center
Item 2(b) Address of Principal Business Office:
3099 Science Park Road, Suite 200
San Diego, CA 92121
Item 2(c) Citizenship: California
Item 2(d) Title of Class of Securities: Common Stock
Item 2(e) CUSIP Number: (None)
Item 3 The person(s) filing is(are):
(b) [_] Bank as defined in Section 3(a)(6) of the Act.
(e) [_] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940.
(g) [_] Parent Holding Company in accordance with
Section 240.13d-1(b)(1)(ii)(G).
Item 4 Ownership
(a) Amount Beneficially Owned: 339,000
(b) Percent of Class: 5.6%
(c) Number of shares as to which such person has:
i) sole power to vote or to direct the vote 339,000
ii) shared power to vote or to direct the vote -0-
iii) sole power to dispose or to direct the disposition of
339,000
iv) shared power to dispose or to direct the disposition of
-0-
<PAGE>
CUSIP No. _______________ Page 4 of 5 Pages
Item 5 Ownership of 5% or Less of a Class:
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner
of more that five percent of the class of securities, check the
following [_]
Item 6 Ownership of More than 5% on Behalf of Another Person: N/A
Item 7 Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company. N/A
Item 8 Identification and Classification of Members of the Group: N/A
Item 9 Notice of Dissolution of the Group: N/A
<PAGE>
CUSIP No. _______________ Page 5 of 5 Pages
Item 10 Certification
By signing below, I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose of and do not have the effect of
changing or influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any transaction having
such purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 13, 1997
---------------------------------------
Date
/s/ Ivor Royston
---------------------------------------
Signature
Ivor Royston, President and
Chief Executive Officer
---------------------------------------
Name/Title
